Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Laura Klüner

Dr. med., M.Sc.

DPhil Student

I am from Germany where I earned a BSc in Physics, an MSc in Medical Physics, my medical degree and a medical doctoral grade (Dr. med.). I received the Rhodes Scholarship (Germany & Hertford, 2019) to read for a DPhil at Oxford University, working under the supervision of Professor Antoniades and Professor Neubauer in the Division of Cardiovascular Medicine.

My research focusses on discovering new imaging biomarkers for cardiovascular risk prediction using computed tomography. In the previous work of our group, novel computed tomography (CT)-based algorithms were developed in order to detect changes of perivascular adipose tissue (PVAT) around inflamed coronary arteries. In this process, the perivascular fat attenuation (FAI) index was implemented which maps these spatial changes of perivascular fat attenuation on computed tomography angiography (CTA). Moreover, radiotranscriptomics was applied which showed that radiotranscriptomic signature of PVAT texture detects additional disease-related changes to PVAT composition.

In my project, I am aiming to apply novel radiotranscriptomic approaches and artificial intelligence, to develop new biomarkers to detect inflammation in the human adipose tissue, flagging individuals with metabolically unhealthy obesity, who are at risk for heart attacks and strokes. Specifically, I will combine the FAI-index with high-risk plaque features (HRP) in order to build an overall index for coronary inflammation. By enabling accurate cardiometabolic risk reclassification, this project will facilitate the deployment of personalised medicine in primary and secondary prevention.